Which clinical indications in orthopedic and pain management is PRP used for?

PRP isn’t a one-trick injection, and that’s both its strength and the place where most clinics get it wrong. You’re looking at a tool with the strongest backing in chronic tendinopathies and mild-to-moderate joint arthritis, with a wider working list that runs through spine, muscle, ligament, foot and ankle, and as a surgical adjunct. The honest move is to match each indication to its evidence tier instead of selling the whole list as equally proven.

Which chronic tendinopathies are most commonly treated with platelet-rich plasma injections?

Chronic tendinopathy is the cleanest fit for PRP because the underlying problem isn’t inflammation, it’s failed healing. You’ve got a degenerated tendon that the body stopped repairing, and PRP delivers a fresh bolus of growth factors to restart that cascade. That biology shows up most consistently in five tendons your patients will recognize by name.

• Lateral epicondylitis: RCT and meta-analysis support; more durable relief than steroid at 6 to 12 months, steroid wins only in the first weeks.
• Patellar tendinopathy: VISA-P and return-to-sport gains when paired with continued eccentric loading after injection.
• Achilles tendinopathy: Mid-substance responds reasonably; insertional disease is more resistant and needs careful peritendinous technique.
• Rotator cuff and gluteal tendinopathy: Partial-thickness cuff tears respond when substance is intact; gluteal tendinopathy has Level II evidence over steroid at two years.

How is PRP applied in the treatment of knee, hip, and other joint osteoarthritis?

Knee OA is where PRP earned its joint-injection credentials, and the playbook around it is now mature enough to apply, with adjustments, to other joints. You’re trading the fast-acting but chondrotoxic profile of cortisone for slower onset and more durable benefit. The technical piece that decides outcomes is accuracy of delivery, and outside the knee that means image guidance every time.

1. Knee (KL 1-3): Superolateral approach under ultrasound or fluoroscopy; outperforms HA and saline at 6 to 12 months in pooled trials.
2. Hip, shoulder, ankle, small joints: Image-guided delivery is required; blind hip injections miss too often to be acceptable.
3. Dosing pattern: Single injection or a series of 2 to 3, two to four weeks apart; multi-injection favored in higher-grade or partial-response cases.
4. Peri-procedure: Stop NSAIDs 5 to 7 days before and 7 to 14 days after; avoid impact loading for 48 to 72 hours; gradual return to activity.
5. Re-treatment: A single booster at 9 to 12 months is the common cadence for patients who responded to the initial series.

What role does PRP play in acute muscle strains, tears, and contusions in athletes?

Acute muscle injury is the indication where the enthusiasm in clinic outruns the trial data. You’ll see PRP offered routinely for hamstring strains in pro and college sports, but the randomized evidence is genuinely mixed. The honest framing for athletes is that PRP is one piece of a structured rehab program, not a shortcut around it.

• Hamstring strains: Most studied muscle indication; some RCTs show faster return to play, others show no acceleration over rehab alone.
• Grade matters: Grade 1 heals too fast for PRP to add value; grade 2 partial musculotendinous tears are the typical target; grade 3 ruptures need surgery with PRP only as an adjunct.
• Timing window: Most clinicians inject 5 to 14 days post-injury, after the initial bleed organizes and before scar matures.
• WADA status: Removed from the WADA prohibited list in 2011, so it’s competition-legal at all levels, though team and league rules still apply.

Which ligament injuries, including partial UCL and MCL tears, are candidates for PRP therapy?

Ligaments behave differently than tendons, and that drives which tears are real PRP candidates. You’re looking for partial-thickness injuries in clinically important stabilizers where reconstruction would be premature but conservative care has stalled. Complete ruptures in poorly contained environments like the ACL aren’t standalone candidates because the biology won’t cooperate.

• UCL partial tears (throwing athletes): 70 to 80 percent return-to-pitching rates with single or double injections plus structured throwing rehab, often avoiding Tommy John.
• MCL grade 1-2 sprains: Ultrasound-guided injection for proximal injuries with persistent laxity or pain; most heal without it, so reserve for stalled cases.
• Chronic ATFL/CFL ankle instability: Modest results; many patients still need a Brostrom-type repair, with PRP serving as an adjunct.
• ACL complete ruptures: Not standalone candidates; PRP applied to graft, bone tunnels, or bridge-enhanced repair only.

How is PRP used in spine and axial pain conditions such as facet arthropathy, sacroiliac joint pain, and discogenic low back pain?

Spine PRP lives in interventional pain practice, where the traditional steroid-and-RFA pathway has clear limitations and biologics are filling specific gaps. You’re delivering into structures with real anatomic risk, so image guidance and operator experience aren’t optional. The three established targets are lumbar facets, the SI joint with its posterior ligaments, and the intervertebral disc.

1. Intradiscal PRP: Fluoroscopic posterolateral approach into the nucleus; 50 to 60 percent response rates at 6 to 12 months in carefully selected contained-degeneration patients.
2. Facet joints: Fluoroscopic or ultrasound-guided capsular injection; more durable than steroid in small comparative studies, though RFA remains the dominant durable option.
3. Sacroiliac joint and ligaments: Joint plus posterior interosseous and dorsal SI ligaments; observational evidence favorable for chronic SI pain that responded only briefly to steroid.
4. Cervical applications: Reserved for high-volume centers given vertebral artery, cord, and nerve root proximity.
5. Risk profile: Post-injection flare common (3 to 7 days), discitis rare but serious, neural or vascular injury possible without strict image-guided technique.

What clinical evidence supports PRP as a surgical adjunct in rotator cuff repair, ACL reconstruction, and cartilage procedures?

The surgical adjunct space is where promising biology has met inconsistent clinical translation. You can see the mechanism working on imaging, but patient-reported outcomes don’t always follow. Three factors explain most of the gap: PRP preparations vary widely, delivered volumes are often too small for the joint environment, and post-op protocols aren’t always built around the biologic window.

• Rotator cuff repair: Modest reduction in structural re-tear rates on MRI, particularly larger tears; pain and function gains smaller and often not significant.
• ACL reconstruction: Faster graft maturation on imaging; KT-1000, IKDC, and return-to-sport rates have not consistently improved over standard reconstruction.
• Cartilage restoration: Microfracture, OATS, and MACI augmentation shows encouraging but heterogeneous results; commonly bundled with HA or bone marrow aspirate now.
• Meniscal repair: Improved healing in red-white and white-white zone tears in some series, especially with fibrin clot constructs; RCT data still maturing.

Which foot, ankle, and small-joint conditions, including plantar fasciitis and hallux rigidus, respond to PRP treatment?

The foot and ankle have turned into one of the highest-yield regions for PRP because the local tissue biology and the limitations of repeated steroid injections both point the same direction. You’ve got fat-pad atrophy and fascial rupture risk on the cortisone side and small-joint cartilage that doesn’t tolerate repeated steroid loads, so a biologic alternative finds real purchase here.

• Plantar fasciitis: Similar to steroid at 4 to 6 weeks; significantly more durable at 6 to 12 months with lower recurrence and none of the fat-pad atrophy risk.
• Posterior tibial tendinopathy: Image-guided injection plus orthotic support works in stage 1 disease; advanced stages need surgical reconstruction.
• Hallux rigidus / first MTP OA: Early-to-moderate grades respond with meaningful pain relief and dorsiflexion improvement, delaying cheilectomy or arthrodesis.
• Osteochondral talar lesions: PRP with arthroscopic microfracture or as primary intra-articular injection in lesions under 1.5 cm squared shows encouraging clinical and imaging results.

How does the strength of evidence vary across PRP indications, and which uses are considered investigational versus established?

The single most common error in patient communication is conflating the well-supported uses with the speculative ones. The evidence sits in tiers, and your job is to map each proposed indication to the tier it actually belongs in. Preparation heterogeneity (leukocyte content, platelet concentration, activation status, volume, injection count) also adds noise that can mask the truth about a well-prepared product used correctly.

What patient selection criteria and contraindications define an appropriate orthopedic or pain management candidate for PRP?

Patient selection is the single biggest predictor of PRP success, and it isn’t soft. You’re filtering against three hard pillars: documented failure of conservative care, anatomic and biologic appropriateness of the target tissue, and absence of safety contraindications. Skip any pillar and the response rate falls fast.